85 related articles for article (PubMed ID: 31562960)
1. Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission.
Konuma T; Kondo T; Mizuno S; Doki N; Aoki J; Fukuda T; Tanaka M; Sawa M; Katayama Y; Uchida N; Ozawa Y; Morishige S; Matsuoka KI; Ichinohe T; Onizuka M; Kanda J; Atsuta Y; Yanada M;
Biol Blood Marrow Transplant; 2020 Mar; 26(3):463-471. PubMed ID: 31562960
[TBL] [Abstract][Full Text] [Related]
2. Myeloablative or reduced-intensity/non-myeloablative hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in adults older than 40 years old - a secondary analysis of a CIBMTR database.
de Oliveira Fernandes Junior I; Arcuri LJ
Ann Hematol; 2024 Feb; 103(2):603-607. PubMed ID: 37940716
[TBL] [Abstract][Full Text] [Related]
3. Comparison of fludarabine-based conditioning regimens in adult cord blood transplantation for myeloid malignancy: A retrospective, registry-based study.
Kurita N; Imahashi N; Chiba S; Tanaka M; Kobayashi H; Uchida N; Kuriyama T; Anzai N; Nawa Y; Nakano N; Ara T; Onizuka M; Katsuoka Y; Koi S; Kimura T; Ichinohe T; Atsuta Y; Kanda J;
Am J Hematol; 2024 Feb; 99(2):236-244. PubMed ID: 38165068
[TBL] [Abstract][Full Text] [Related]
4. Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation.
Rotz SJ; Hamilton BK; Wei W; Ahmed I; Winston SA; Ballard S; Bernard RJ; Carpenter P; Farhadfar N; Ferraro C; Friend BD; Gloude NJ; Hayashi RJ; Hoyle K; Jenssen K; Koo J; Lee CJ; Mariano L; Nawabit R; Ngwube A; Lalefar N; Phelan R; Perkins L; Rao A; Rayes A; Sandheinrich T; Stafford L; Tomlinson K; Whiteside S; Wiedl C; Myers K
Transplant Cell Ther; 2024 May; 30(5):534.e1-534.e13. PubMed ID: 38342136
[TBL] [Abstract][Full Text] [Related]
5. Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.
Walter RB; Sandmaier BM; Othus M; Orvain C; Rodríguez-Arbolí E; Oshima MU; Schoch G; Davis C; Joachim Deeg H; Storb R
Bone Marrow Transplant; 2023 Apr; 58(4):377-385. PubMed ID: 36577856
[TBL] [Abstract][Full Text] [Related]
6. Effects of total body irradiation on hematopoietic cell transplantation outcomes in pediatric acute myeloid leukemia with prior central nervous system involvement.
Takahashi T; Lake AJ; Wachter F; Calderon FA; Dandoy C; Keating AK
Transplant Cell Ther; 2024 May; ():. PubMed ID: 38763417
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemia.
Goyal G; Gundabolu K; Vallabhajosyula S; Silberstein PT; Bhatt VR
Ther Adv Hematol; 2016 Jun; 7(3):131-41. PubMed ID: 27247754
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy.
Itonaga H; Miyazaki Y; Fujioka M; Aoki J; Doki N; Nishida T; Fukuda T; Uchida N; Ueda Y; Uehara Y; Katayama Y; Ota S; Kawakita T; Kato J; Matsuoka KI; Eto T; Onizuka M; Ichinohe T; Atsuta Y; Ishiyama K
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38714756
[TBL] [Abstract][Full Text] [Related]
9. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
Pingali SR; Champlin RE
Bone Marrow Transplant; 2015 Sep; 50(9):1157-67. PubMed ID: 25985053
[TBL] [Abstract][Full Text] [Related]
10. An International Survey of Allogeneic Hematopoietic Cell Transplantation for X-Linked Agammaglobulinemia.
Nishimura A; Uppuluri R; Raj R; Swaminathan VV; Cheng Y; Abu-Arja RF; Fu B; Laberko A; Albert MH; Hauck F; Bucciol G; Bigley V; Elcombe S; Kharya G; Pronk CJH; Wehr C; Neven B; Warnatz K; Meyts I; Morio T; Gennery AR; Kanegane H
J Clin Immunol; 2023 Nov; 43(8):1827-1839. PubMed ID: 37454339
[TBL] [Abstract][Full Text] [Related]
11. Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC).
Niederwieser C; Iacobelli S; Franke GN; Koster L; van Os M; Platzbecker U; Hübel K; Scheid C; Müller LP; Stelljes M; Morozova E; Passweg J; Onida F; Dreger P; Saccardi R; Ladetto M; Salmenniemi U; Bethge W; Poiré X; Kobbe G; McLornan DP; Robin M; Kröger N
Bone Marrow Transplant; 2024 Apr; ():. PubMed ID: 38664589
[TBL] [Abstract][Full Text] [Related]
12. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation.
Gagelmann N; Schuh C; Flossdorf S; Kunadt D; Stelljes M; Blau IW; Brecht A; Bethge W; Schroeder T; Wulf G; Sala E; Bug G; Fleischhauer K; Kröger N;
Am J Hematol; 2024 May; ():. PubMed ID: 38742955
[TBL] [Abstract][Full Text] [Related]
13. Value of Different Comorbidity Indices for Predicting Outcome in Patients with Acute Myeloid Leukemia.
Wass M; Hitz F; Schaffrath J; Müller-Tidow C; Müller LP
PLoS One; 2016; 11(10):e0164587. PubMed ID: 27732646
[TBL] [Abstract][Full Text] [Related]
14. High dose total marrow irradiation (TMI) does not increase long-term toxicity of myeloablative fludarabine/busulfan (FluBu4) conditioning regimen in allogeneic hematopoietic stem cell transplantation (HSCT).
Maahs L; Patel P; Koshy M; Sweiss K; Chen Z; Xu Z; Aydogan B; Rondelli D
Eur J Haematol; 2024 Apr; ():. PubMed ID: 38566462
[TBL] [Abstract][Full Text] [Related]
15. Early Allogeneic Transplantation Favorably Influences the Outcome of Pediatric Acute Myeloid Leukemia-A Retrospective Study in a Single Center Over 2 Decades.
Lo TY; Wang YL; Jaing TH; Chang TY; Wen YC; Chiu CC; Hsiao YW; Chen SH
Transplant Proc; 2024; 56(1):201-210. PubMed ID: 38245493
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine-Based Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in a Pediatric Patient with Sickle Cell Disease: A Case Report.
Builes N
Int J Hematol Oncol Stem Cell Res; 2024 Jan; 18(1):104-109. PubMed ID: 38680715
[TBL] [Abstract][Full Text] [Related]
17. EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant.
Baranwal A; Mangaonkar A; Shah MV; Al-Kali A; Tefferi A; Hogan WJ; Litzow MR; Patnaik MM; Alkhateeb HB
Bone Marrow Transplant; 2024 Apr; 59(4):558-560. PubMed ID: 38216690
[No Abstract] [Full Text] [Related]
18. Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score matching-based study.
Shen Y; Liu M; Shen D; Chu M; Li X; Zhang X; Fan Y; Chen J; Wu D; Hu S; Xu Y
Bone Marrow Transplant; 2024 Apr; ():. PubMed ID: 38615141
[No Abstract] [Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia.
Tolosa-Ridao C; Suárez-Lledó M; Jiménez-Vicente C; Cortés-Bullich A; Merchan B; Martínez-Roca A; Guijarro F; Castaño-Díez S; Rosiñol L; Fernández-Avilés F; Martínez C; Díaz-Beya M; Esteve J; Rovira M; Salas MQ
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38778147
[No Abstract] [Full Text] [Related]
20. Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen.
Robin M; Nibourel O; Tournaire M; Michonneau D; Preudhomme C; Verbanck M; Xhaard A; Adès L; Sicre de Fontbrune F; Sébert M; Fenaux P; Socié G; Peffault de Latour R; Curis E
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38783124
[No Abstract] [Full Text] [Related]
[Next] [New Search]
